Inpharma 1236 - 6 May 2000

■ Interleukin-4(38-37)-PE38KDEL* shows antitumouractivity in patients with glioblastoma, reportresearchers from the US and Germany. In thismulticentre study, 31 patients with grade IVglioblastoma which was not responsive to surgery andradiotherapy received intratumoural infusions ofinterleukin-4(38-37)-PE38KDEL for up to 4 days.Patients were followed-up for 1–16 months. Of the 29patients who were evaluable for efficacy, 4 (13%) hadcomplete remissions, 14 (48%) had a partial response(> 50% reduction in tumour mass) and 7 (24%)experienced disease stabilisation. Approximately onethird of patients experienced adverse effects(consistent with tumour cell death and a subsequentinflammatory response) during, or immediately after,treatment.* Neurocrine Biosciences; phase II

Neurocrine Biosciences Inc. Neurocrine Biosciences announces positivefindings in phase I/II malignant brain tumor clinical trial. Media Release : [3pages], 19 Apr 2000. Available from: URL: http://www.neurocrine.com 800820350

1

Inpharma 6 May 2000 No. 12361173-8324/10/1236-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved